PowderMRP Under Process
Official PMBI MRP is being updated for catalog code 2573.
Locate Jan Aushadhi KendraClinical Overview
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhale the contents of 1 capsule once daily at the same time each day (preferably in the evening or morning) using the specialized DPI device. Rinse mouth thoroughly with water and spit out after use.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nasopharyngitis, headache, upper respiratory tract infection, oral candidiasis, dysphonia. Rare/Severe: Paradoxical bronchospasm, QTc prolongation, and hypokalemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Once-daily administration only; do NOT exceed 1 dose in 24 hours. Capsules are for oral inhalation ONLY; do not swallow. Rinse mouth after inhalation. Not for acute rescue relief.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Hydroquinone 2%, Mometasone 0.1% and Tretinoin 0.025% Cream
Hydroquinone, Tretinoin, and Fluocinolone Acetonide is the gold-standard Triple Combination Cream (Kligman's formula) for refractory melasma. Hydroquinone (2-4%) competitively inhibits tyrosinase, blocking melanin pigment synthesis; Tretinoin (0.05%) accelerates epidermal turnover and keratinocyte shedding, facilitating hydroquinone penetration and dispersing melanin; and Fluocinolone Acetonide (0.01%), a mild-to-moderate topical corticosteroid, suppresses melanocyte inflammation and counteracts the irritant dermatitis of hydroquinone and tretinoin. Indicated for the short-term moderate-to-severe melasma of the face.
Mometasone Furoate Cream 0.1%
Mometasone Furoate (0.1% w/w cream/ointment) is a high-potency (Class II) synthetic topical corticosteroid on the WHO Model List of Essential Medicines. It features a high therapeutic index, providing robust anti-inflammatory and anti-pruritic activity with significantly lower systemic absorption and cutaneous atrophogenic potential than older fluorinated steroids. Indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis.
Indacaterol 110mcg + Glycopyrronium 50mcg powder for Inhalation
Indacaterol (110mcg) and Glycopyrronium (50mcg Powder for Inhalation) is a dual-bronchodilator combination (LABA + LAMA) on the WHO Model List framework. Indacaterol relaxes airway smooth muscle by stimulating beta-2 adrenergic receptors; glycopyrronium competitively blocks muscarinic M3 receptors on bronchial smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction. Combining two distinct bronchodilator mechanisms delivers superior lung function improvement (FEV1), dyspnea reduction, and exacerbation prevention compared to either monotherapy. Indicated for once-daily maintenance bronchodilator treatment of Chronic Obstructive Pulmonary Disease (COPD).
Mometasone Aqueous Nasal Spray 0.05%w/v (nasal suspension in a pressurise container)
Mometasone Furoate Aqueous Nasal Spray (0.05% w/v / 50mcg per actuation) is a topically active synthetic glucocorticoid on the WHO Model List of Essential Medicines. It exhibits high topical anti-inflammatory potency on nasal mucosa with undetectable systemic bioavailability (<0.1%), downregulating pro-inflammatory cytokines and allergic cellular infiltration. Indicated for treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children >=2 years, and treatment of nasal polyps in adults >=18 years.